Welcome to our dedicated page for DIH Holdings US SEC filings (Ticker: DHAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the FDA path of a robotic rehabilitation device while decoding revenue recognition rules can make DIH Holdings US (DHAI) filings feel like a clinical trial in patience. Each 10-K hides pages of R&D spend, device adoption metrics and virtual-reality software agreements, and every 8-K announces material events that may shift the competitive landscape overnight. Stock Titan turns those dense documents into clear takeaways, so you can stop combing through footnotes and start focusing on what moves the market.
Our platform automatically ingests every DIH Holdings US quarterly earnings report 10-Q filing, proxy statement executive compensation table and 8-K material events explained update the moment EDGAR posts them. AI-powered summaries surface where product revenue grew, how clinical studies progressed and whether new regulatory hurdles emerged鈥�understanding DIH Holdings US SEC documents with AI is finally possible. Need real-time alerts on DIH Holdings US Form 4 insider transactions? We flag each executive stock move, complete with context, so you can gauge insider confidence without refreshing EDGAR all day.
Whether you鈥檙e asking, 鈥淲hat does DIH report in its annual report 10-K?鈥� or searching for 鈥淒IH Holdings US earnings report filing analysis,鈥� the answers live here. Explore:
- DIH Holdings US insider trading Form 4 transactions and real-time notifications
- Device sales trends inside the DIH Holdings US annual report 10-K simplified
- Segment margins and backlog in each DIH Holdings US quarterly earnings report 10-Q filing
- Board pay details from the DIH Holdings US proxy statement executive compensation schedule
- Regulatory breakthroughs in DIH Holdings US 8-K material events explained
Extra Space Storage Inc. (NYSE: EXR) filed a Form S-8 on 1 Aug 2025 to register 6,500,000 additional shares of common stock for issuance under its Amended & Restated 2015 Incentive Award Plan. The filing incorporates by reference the company鈥檚 2024 10-K, 2025 Q1 & Q2 10-Qs and recent 8-Ks, thereby making those documents part of the prospectus delivered to plan participants. The company is a large accelerated filer and will offer the shares as awards are granted, exercised or distributed.
The S-8 includes customary MGCL-based indemnification language for directors and officers, a list of exhibits (legal opinion, auditor consent, updated plan document, etc.) and undertakings to file post-effective amendments if material changes occur. No new financial results or valuation metrics are disclosed; the statement鈥檚 sole purpose is to facilitate future equity compensation grants. Upon issuance, these shares will increase the public float and could dilute existing stockholders, but they also expand the company鈥檚 ability to attract and retain talent.
Nikul Patel, a director of Champion Homes, Inc. (NYSE: SKY), filed a Form 4 disclosing the grant of 2,259 restricted stock units (RSUs) on 07/24/2025 under the company鈥檚 2018 Equity Incentive Plan. Each RSU converts into one share of common stock and will vest in full on the earlier of the first anniversary of the vesting commencement date or the 2026 Annual Meeting, assuming continued board service.
The award, recorded at an indicative reference price of $66.39 per share, increases Patel鈥檚 direct beneficial ownership to 6,679 shares. No derivative instruments were involved, and no cash changed hands.
This appears to be a routine director equity grant designed to align compensation with shareholder interests; it carries no immediate strategic, operational, or financial implications for Champion Homes.
FAQ
What is the current stock price of DIH Holdings US (DHAI)?
What is the market cap of DIH Holdings US (DHAI)?
What is the core focus of DIH Holdings US?
How do DIH Holdings US devices benefit patients?
What is the primary business model of the company?
How does DIH Holdings US stand out in the rehabilitation technology market?
In which global markets does DIH Holdings US operate?
What role does clinical research play in the company鈥檚 operations?
Who are the likely customers for DIH Holdings US's products?
How does DIH Holdings US ensure the quality and reliability of its devices?
